EGRX.US Eagle Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.2500 USD
Close of Nov 14, 2026
0.0010 3.94
Market cap
USD 3.29M
P/E
0.2x
P/B
0.16x
ROE
8.7%
Dividend yield
53.11%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is EGRX.US undervalued?

Graham number

The Graham number of Eagle Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eagle Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Eagle Pharmaceuticals Inc yet.

Eagle Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of …

Full company profile